No benefit from addition of aliskiren to 'gold standard' ACE inhibitor

In one of the largest trials ever conducted in patients who have heart failure with reduced ejection fraction -- a measure of the heart's ability to pump blood -- the investigational drug aliskiren failed to show superiority over full-dose treatment with the existing 'gold standard' therapy, the angiotensin-converting enzyme inhibitor enalapril, researchers reported.
Source: ScienceDaily Headlines - Category: Science Source Type: news